Alnylam Pharmaceuticals lowered its full-year 2026 TTR product sales guidance by approximately $200 million, citing slower demand and lessons from the initial launch phase in the evolving ATTR-CM market, including normalized second-line volume growth after pent-up patient demand was met. The company announced the revision alongside its second-quarter 2026 results on July 30, 2026. Its shares fell $81.14 on the news. The earlier account described the decline as approximately 28%, to close at $205.48, while the latest update characterizes the loss as about 25%. The move came despite strength across the biotech sector. Kirby McInerney LLP is investigating whether Alnylam or members of its senior management violated federal securities laws or engaged in other unlawful business practices. No lawsuit has been filed, and the investigation remains ongoing. Investors and others with relevant information may contact Lauren Molinaro at no cost.